Abstract
Background: Severe asthma is frequently associated with chronic rhinosinusitis with nasal polyps (CRSwNP), contributing to poor asthma control. In literature, the use of mepolizumab in patients with severe asthma and CRSwNP has shown to reduce exacerbations and improve quality of life.
Aim: To compare the impact of mepolizumab in severe asthma patients with and without CRSwNP regarding several outcomes.
Materials and methods: Multicenter retrospective study of severe asthma patients under mepolizumab in 2020.
Results: 22 severe asthma patients were included and both groups - with and without CRwNP - were homogeneous concerning sex, age, BMI and smoking habits.
Discussion: Although there were no differences in outcomes between the two groups it seems that patients with CRSwNP have a greater need for short-term use of OCS followed by a greater reduction after mepolizumab. In patients with CRSwNP mepolizumab had an important role in improving quality of life, evidence by a reduction in the total score of ACT and SNOT-22
CRSwNP n=12.0(54.5) | Without CRSwNP n=10.0(45.5) | p-value Δ | |||
T/0 | T/6-12M | T/0 | T/6-12M | ||
ACT SNOT-22 Low dose OCS regime Short-term use OCS+ Asthma exacerbations+ | 10.0[9.8–14.3] 65.8±14.6 6.0(50.0) 4.5[2.0–10.5] 5.0[2.0–12.0] | 22.0[20.6–22.3] 24.3±11.5 3.0(25.0) 0.0[0.0–0.0] 1.0[0.0–1.0] | 9.0[7.0–11.0] - 6.0(60.0) 3.5[1.8–5.0] 4.5[2.6–10.0] | 21.5[19.3–23.8] - 3.0(30.0) 1.0[0.0–2.3] 1.5[1.0–2.3] | 0.222 - 0.907 0.055 0.268 |
Eosinophilia | 585.0[310.0–1725.0] | 100.0[82.5–100.0] | 620.0[300.0–1115.0] | 80.0[12.5–100.0] | 0.843 |
Pre-bronchodilator FEV1(%) | 74.1±28.1 | 77.2±19.0 | 67.9±21.5 | 77.0±11.4 | 0.573 |
Data present as n(%),mean±standard deviation or median[range]; T0–beginning of mepolizumab; T/6-12M–6-12 months after; Δ–variation between T/6-12M and T0. +previous year; |
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA889.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021